366 related articles for article (PubMed ID: 806016)
21. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
[TBL] [Abstract][Full Text] [Related]
22. Lumbar puncture and subdural hygroma and hematomas in hematopoietic cell transplant patients.
Openshaw H; Ressler JA; Snyder DS
Bone Marrow Transplant; 2008 May; 41(9):791-5. PubMed ID: 18246118
[TBL] [Abstract][Full Text] [Related]
23. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid.
McCully CL; Balis FM; Bacher J; Phillips J; Poplack DG
Lab Anim Sci; 1990 Sep; 40(5):520-5. PubMed ID: 2170754
[TBL] [Abstract][Full Text] [Related]
24. Cytological changes in the cerebrospinal fluid following intrathecal methotrexate treatment. I. Observations in adult meningeal leukemia.
Péter A
Confin Neurol; 1974; 36(3):186-96. PubMed ID: 4533245
[No Abstract] [Full Text] [Related]
25. Intrathecal chemotherapy for patients with meningeal carcinomatosis.
Yoshida S; Morii K
Surg Neurol; 2005 Jan; 63(1):52-5; discussion 55. PubMed ID: 15639526
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics.
Bleyer AW
Cancer Treat Rep; 1977 Nov; 61(8):1419-25. PubMed ID: 579164
[TBL] [Abstract][Full Text] [Related]
27. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
Glantz MJ; Jaeckle KA; Chamberlain MC; Phuphanich S; Recht L; Swinnen LJ; Maria B; LaFollette S; Schumann GB; Cole BF; Howell SB
Clin Cancer Res; 1999 Nov; 5(11):3394-402. PubMed ID: 10589750
[TBL] [Abstract][Full Text] [Related]
28. Kinetics of elimination of methotrexate from the cerebrospinal fluid space of monkeys after ventriculolumbar perfusion.
Merker PC; Mehta BM; Cantor ML; Hutchison DJ
Cancer Treat Rep; 1977 Jul; 61(4):603-11. PubMed ID: 406994
[No Abstract] [Full Text] [Related]
29. Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs.
Ramu A; Fusner JE; Blaschke T; Glaubiger DL
Cancer Treat Rep; 1978 Oct; 62(10):1465-70. PubMed ID: 581360
[TBL] [Abstract][Full Text] [Related]
30. [Radioisotope ventriculography for functional evaluation of the Ommaya Reservoir (author's transl)].
Yamada K; Ushio Y; Hayakawa T; Mogami H; Bremer AM; West CR
No Shinkei Geka; 1980 Jan; 8(1):49-54. PubMed ID: 7360305
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction.
Lippens RJ; Winograd B
Pediatr Hematol Oncol; 1988; 5(2):115-24. PubMed ID: 3152957
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of leukemic infiltrations of the central nervous system. Preliminary communication].
Swencz-Szczepanik K; Kołakowska-Polubiec K; Królikiewicz H; Kaczyńska D; Maj S; Pawelski S
Acta Haematol Pol; 1978; 9(4):257-61. PubMed ID: 282763
[TBL] [Abstract][Full Text] [Related]
33. Current status of intrathecal chemotherapy for human meningeal neoplasms.
Bleyer WA
Natl Cancer Inst Monogr; 1977 Dec; 46():171-8. PubMed ID: 580638
[TBL] [Abstract][Full Text] [Related]
34. Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates.
Salzer W; Widemann B; McCully C; Adamson PC; Balis FM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):235-40. PubMed ID: 11592346
[TBL] [Abstract][Full Text] [Related]
35. Lumbar spinal fluid collections in children treated with intrathecal chemotherapy: elevated CSF protein as a diagnostic clue.
Almanjomi F; Armstrong D; Abla O; Naqvi A; Weitzman S; Hitzler J
Pediatr Blood Cancer; 2008 Aug; 51(2):295-8. PubMed ID: 18454469
[TBL] [Abstract][Full Text] [Related]
36. Monitoring central nervous system methotrexate levels via subcutaneous reservoir. Sources of errors in sampling and their avoidance.
Maguire LC; Corder MP; Wiesenfeld M
Cancer Clin Trials; 1980; 3(4):337-40. PubMed ID: 6893574
[TBL] [Abstract][Full Text] [Related]
37. Implanted system for intraventricular drug infusion in central nervous system tumors.
Dakhil S; Ensminger W; Kindt G; Niederhuber J; Chandler W; Greenberg H; Wheeler R
Cancer Treat Rep; 1981; 65(5-6):401-11. PubMed ID: 6263475
[TBL] [Abstract][Full Text] [Related]
38. Intrathecal cytostatic therapy of meningeal carcinomatosis. Autoradiographic investigations of the CSF cells.
Engelhardt P
J Neurol; 1976 Oct; 213(4):309-15. PubMed ID: 62030
[TBL] [Abstract][Full Text] [Related]
39. A pharmacokinetic model for predicting the concentration of methotrexate in plasma subsequent to intrathecal injection.
Ramu A; Fusner JE
Isr J Med Sci; 1979 Jun; 15(6):494-9. PubMed ID: 582316
[TBL] [Abstract][Full Text] [Related]
40. Intrathecal methotrexate-induced neurotoxicities.
Nelson RW; Frank JT
Am J Hosp Pharm; 1981 Jan; 38(1):65-8. PubMed ID: 7011005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
